Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

The Food and Drug Administration is set to treat the application under its priority program to accelerate the review of ...

Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease’s progression - ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Analysts had prior to the results called the trials a long shot, whereas Novo itself had referred it as a "lottery ticket." ...

Fintel reports that on November 28, 2025, Goldman Sachs maintained coverage of Novo Nordisk A (NYSE:NVO) with a Buy ...

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, ...

Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. The company revealed ...